Allyson Hart1,2, Terri L Blackwell3, Misti L Paudel4,5, Brent C Taylor5,6, Eric S Orwoll7, Peggy M Cawthon3, Kristine E Ensrud2,5,6. 1. Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota. 2. Department of Medicine, University of Minnesota, Minneapolis. 3. Research Institute, California Pacific Medical Center, San Francisco. 4. NORC at the University of Chicago, Health Care Department, Bethesda, Maryland. 5. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis. 6. Center for Chronic Disease Outcomes Research, VA Health Care System, Minneapolis, Minnesota. 7. Bone and Mineral Unit, Oregon Health and Science University, Portland.
Abstract
BACKGROUND: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. METHODS: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. RESULTS: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95% confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95% CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. CONCLUSIONS: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.
BACKGROUND: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. METHODS: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. RESULTS: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95% confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95% CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. CONCLUSIONS: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.
Authors: Allyson Hart; Misti L Paudel; Brent C Taylor; Areef Ishani; Eric S Orwoll; Peggy M Cawthon; Kristine E Ensrud Journal: J Am Geriatr Soc Date: 2013-09-03 Impact factor: 5.562
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Christine K Liu; Asya Lyass; Joseph M Massaro; Ralph B D'Agostino; Caroline S Fox; Joanne M Murabito Journal: J Gerontol A Biol Sci Med Sci Date: 2013-08-02 Impact factor: 6.053
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: O Alison Potok; Ronit Katz; Nisha Bansal; David S Siscovick; Michelle C Odden; Joachim H Ix; Michael G Shlipak; Dena E Rifkin Journal: Am J Kidney Dis Date: 2020-07-16 Impact factor: 8.860
Authors: Chris P Verschoor; David T S Lin; Michael S Kobor; Oxana Mian; Jinhui Ma; Guillaume Pare; Gustavo Ybazeta Journal: Clin Epigenetics Date: 2021-08-23 Impact factor: 6.551
Authors: Kyoung Min Kim; Li-Yung Lui; Warren S Browner; Jane A Cauley; Kristine E Ensrud; Deborah M Kado; Eric S Orwoll; John T Schousboe; Steven R Cummings Journal: J Gerontol A Biol Sci Med Sci Date: 2021-06-14 Impact factor: 6.053